Asthma Allergic

5

Review clinical trials related to Asthma Allergic. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Plant Stanol Esters and Preventing Asthma Symptoms

Plant stanols are known to lower low-density lipoprotein cholesterol. However, studies have suggested that these compounds also influence the immune system. Asthmatic responses are predominantly T helper (Th)2 cell dependent, while plant stanols were previously found to activate Th1 cells and shift the immune response away from the Th2 cell dominant asthmatic response. The question now is whether this also translates into a reduction of clinical symptoms in asthma patients.The primary objective of this study is to demonstrate clinical benefits of prolonged consumption of plant stanols (delivered via plant stanol esters) in asthma patients. The secondary objectives are to evaluate the mechanisms via which plant stanols modulate the immune system and to evaluate the effects of plant stanol ester consumption on cardiovascular (CVD) risk parameters.

Participants needed: 160
Trial details
Age: 18-70Biological sex: AllType: InterventionalSponsor: Maastricht University Medical CenterUpdated: Jun 25, 2026Locations: 1
Eligibility criteria

Diagnosed with allergic asthma (GINA step 1-4) which is in a stable phase at the... [+6]

Currently smoking or quitted smoking in the past year, with a maximum of 10 pack... [+7]

Status: Recruiting

Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses.

A Randomized, Double-Blinded, Placebo-Controlled, Prospective, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Subcutaneous Immunotherapy in Patients With Rhinitis/Rhinoconjunctivitis With or Without Mild to Moderate Asthma Sensitized to cupressaceae and grasses.

Participants needed: 180
Trial details
Phase: Phase 3Age: 12-65Biological sex: AllType: InterventionalSponsor: Inmunotek S.L.Updated: May 13, 2025Locations: 27
Eligibility criteria

Written informed consent. [+10]

Subjects with positive prick test to other aeroallergens except for sensitisatio... [+16]

Status: Recruiting

Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites

A double-blinded, placebo-controlled, prospective, multicenter randomized of 2 active treatment groups, compared to 1 placebo group, for the determination of the efficacy and safety of subcutaneous immunotherapy in patients with rhinitis/rhinoconjunctivitis with or without asthma, sensitised to Dermatophagoides pteronyssinus and /or Dermatophagoides farinae.

Participants needed: 150
Trial details
Phase: Phase 3Age: 12-65Biological sex: AllType: InterventionalSponsor: Inmunotek S.L.Updated: May 13, 2025Locations: 32
Eligibility criteria

Written informed consent. [+13]

Subjects who have received previous immunotherapy in the previous 5 years to dan... [+13]

Status: Recruiting

Efficacy and Safety Evaluation for the Treatment of Allergy Against Grass and Olive Pollen

Prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial of efficacy and safety with subcutaneous immunotherapy in patients with mild to moderate rhinitis / rhinoconjunctivitis with or without mild to moderate asthma sensitized to grasses and olive

Participants needed: 180
Trial details
Phase: Phase 3Age: 12-65Biological sex: AllType: InterventionalSponsor: Inmunotek S.L.Updated: May 7, 2025Locations: 32
Eligibility criteria

Subject who has signed the informed consent. [+10]

Subjects polysensitized to other aeroallergens with the exception of epithelia w... [+16]

Status: Not yet recruiting

Biologics and Sublingual Immunotherapy

Most current studies involve using a biological drug to increase the safety of allergen immunotherapy (AIT) especially in the treatment of food allergies, to avoid the risk of anaphylaxis. However, adding Xolair® to AIT may improve the therapy's effectiveness. There are still few observations on this topic, especially in patients with house dust mite (HDM)-driven asthma.

Participants needed: 150
Trial details
Phase: Phase 4Age: 18-65Biological sex: AllType: InterventionalSponsor: Medical University of SilesiaUpdated: Sep 7, 2023
Eligibility criteria

A total IgE between 30-700 IU/mL [+3]

Sensitisation to other allergens with clinical signs not related to HDM [+4]